PA
EW icon

Procyon Advisors’s Edwards Lifesciences EW Stock Holding History

Procyon Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,495
Closed -$398K – 517
2025
Q1 		$398K Sell
5,495
-13
-0.2% -$930 0.02% 422
2024
Q4 		$408K Sell
5,508
-132
-2% -$9.24K 0.03% 371
2024
Q3 		$373K Sell
5,640
-55
-1% -$4K 0.03% 399
2024
Q2 		$526K Sell
5,695
-351
-6% -$31.1K 0.04% 304
2024
Q1 		$578K Sell
6,046
-17
-0.3% -$1.43K 0.04% 303
2023
Q4 		$462K Buy
6,063
+384
+7% +$26.7K 0.04% 329
2023
Q3 		$393K Buy
+5,679
New +$456K 0.04% 337
2020
Q3 		– Sell
-434
Closed -$30K – 454
2020
Q2 		$30K Buy
434
+5
+1% +$355 0.02% 471
2020
Q1 		$27K Buy
429
+315
+276% +$22.7K 0.02% 425
2019
Q4 		$9K Buy
+114
New +$8.9K 0.01% 680

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Procyon Advisors's EW Position: Q2 2025 in Review

Procyon Advisors sold out of Edwards Lifesciences (EW) in Q2 2025, closing a stake of 5,495 shares — an estimated $398K sold.

Procyon Advisors first reported a position in EW in Q4 2019 and held it in 10 quarters. The position peaked at $578K in Q1 2024. 1,260 funds tracked by Wall St. Rank hold EW as of Q2 2025.

  • Procyon Advisors reported no remaining Edwards Lifesciences position as of Q2 2025 after selling out during the quarter.
  • Procyon Advisors sold 5,495 Edwards Lifesciences shares in Q2 2025, an estimated $398K.
  • Procyon Advisors first reported a position in Edwards Lifesciences in Q4 2019 and held it in 10 quarters.
  • Procyon Advisors's Edwards Lifesciences position peaked at $578K in Q1 2024.
  • 1,260 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.

Based on Procyon Advisors's 13F filing for Q2 2025, filed 9 Jul 2025.